Microfluidics in Radiopharmacy: A Revolution in PET Isotope Production
The synthesis of short-lived radio-isotopes for Positron Emission Tomography (PET) is on the verge of a fundamental change. Traditional production in central cyclotron facilities is accompanied by significant losses due to radioactive decay during transport to the hospital. Pharma In-Minute is developing a microfluidic platform that addresses this challenge by enabling 'on-demand' production in the hospital pharmacy itself.
The Process in Detail
Our system utilizes advanced microfluidic chips, often fabricated from glass or transparent polymers, which visualize an isotope glow during the synthesis process. These chips contain channels with a diameter smaller than a human hair, allowing reagents to be mixed and reacted with utmost precision.
The process scheme typically includes the following steps:
- Target Irradiation: A liquid target is exposed to a proton beam in a compact, on-site installed particle accelerator.
- Microfluidic Synthesis: The activated fluid flows through the chip, where it is sequentially mixed with precursors and reagents in specific reaction chambers.
- Purification & Formulation: The final product is immediately purified online and formulated into a sterile, injectable radiopharmaceutical.
- Quality Control: Integrated sensors continuously monitor yield, purity, and radioactivity concentration.
Benefits and Future Vision
The benefits are manifold: elimination of transport losses, flexibility in isotope composition, reduced radiation exposure for personnel, and a drastic reduction in initial investment compared to conventional facilities. This technology opens the door to personalized radiopharmacy, where isotopes are precisely tailored to the needs of the individual patient and the specific clinical protocol.
The future lies in integrated, fully automated modules that seamlessly connect to the hospital pharmacy, making nuclear medicine more accessible and expanding diagnostic capabilities.
Comments